Agilent Technologies

Ottergemsesteenweg Zuid 808/bus 317

9000 Gent

BE

Agilent Technologies

Foundation date

01/01/1999

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

Agilent inspires and supports discoveries that advance the quality of life. We provide life science, diagnostic, and applied market laboratories worldwide with instruments, services, consumables, applications, and expertise. Agilent enables customers to gain the answers and insights they seek ---- so they can do what they do best: improve the world around us.

The Agilent SLIMS platform provides technology that advances that goal, adding to Agilent’s substantial solutions. SLIMS traces its roots to 2002, where, in Ghent (Belgium), the startup company Genohm began as a small two-person bio-informatics shop. SLIMS today focuses on guaranteeing compliance, traceability and lab data management in highly complex and continuously evolving lab environments. Today, Agilent SLIMS is serviced by a global team of 60+ highly trained software and life sciences engineers. For more information on the SLIMS platform, visit: https://explore.agilent.com/Agilentslims.

The Alissa Clinical Informatics Platform delivers innovative NGS and CGH data analysis, variant interpretation and reporting modules designed to optimize workflows across technologies and applications. On the platform, integrate read alignment to reporting for greater efficiency. Interpret NGS and CGH data on a single sample to call CNVs via NGS data and run arrays as NGS tests for greater diagnostic yield. Shorten time to results by seamlessly flowing from raw data alignment, to annotations, to mutation categorisation. For more information on the Alissa Clinical Platform, visit: https://www.agilent.com/en/product/next-generation-sequencing/clinical-informatics-platform

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    14 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022

Jobs by Agilent Technologies